Neuronetics Shareholder Chernett Jorey Sells 7.4 Million Shares, Drops Below 5% Reporting Threshold

Jorey retained a 2.7% stake as the treatment-system company sought fresh capital and relief from loan requirements.

Share
Neuronetics Shareholder Chernett Jorey Sells 7.4 Million Shares, Drops Below 5% Reporting Threshold

Chernett Jorey sold 7.4 million shares of Neuronetics, which makes brain-stimulation treatment systems, Friday and fell below 5%, the ownership-reporting threshold. His amended SEC ownership disclosure Monday marked his exit from that reporting requirement, with a remaining stake of 2.7%.

Friday's sale dominates the trading

Jorey's largest listed sale involved 7,408,602 shares Friday at an average price of $1.16. The reported trades covered six dates from October 30 through Friday, with 8,556,962 shares sold and 58,000 bought across seven transactions.

The sales left Jorey holding 2,104,026 shares, with sole control over voting and selling them. He bought that remaining position using personal funds, at an aggregate cost of approximately $4.1 million on an average-cost basis.

The ownership percentage uses 77,728,311 shares outstanding as of October 28. Jorey initially filed his ownership disclosure on March 31, 2026.

Fresh capital and loan relief

Neuronetics priced its offering Tuesday at $1.60 per share, with approximately $30 million in expected gross proceeds, according to its announcement. It plans to use part of the net proceeds to repay its term loan.

A credit agreement revised November 5 would relax certain revenue requirements if conditions are met, including a loan prepayment of at least $15 million. Neuronetics said meeting those conditions should address the risk identified in recent quarterly filings that it might struggle to keep operating.

Systems, sessions and Greenbrook clinics

Neuronetics sells its NeuroStar Advanced Therapy System and recurring treatment sessions, mainly to U.S. psychiatrists. The office-based system uses transcranial magnetic stimulation, a non-invasive treatment that stimulates brain areas associated with mood.

The system has FDA clearance for major depressive disorder, adult obsessive-compulsive disorder and anxiety symptoms in adults with depression. Neuronetics also runs 93 Greenbrook treatment centers offering the therapy.

Clinic revenue and treatment sessions account for most of its sales. Revenue totaled $149.2 million for the year ended December 31, 2025.

The credit amendment automatically terminates unless its conditions are met or waived by November 30.

Sources

More on Neuronetics

All Neuronetics (STIM) coverage →